Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.2M fell 41.1% year over year, behind the -28.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 20.0% from the prior quarter. Over 3 fiscal years it compounded at +4.4% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -41.1% toward the trailing-twelve-month pace of -28.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 13.05M USD
- Year-over-year change
- -20.9%
- 4-year CAGR
- +45.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.05M | -20.9% |
| FY2024 | 2024-12-31 | 16.5M | +7.8% |
| FY2023 | 2023-12-31 | 15.31M | +33.5% |
| FY2022 | 2022-12-31 | 11.47M | +288.7% |
| FY2021 | 2021-12-31 | 2.95M | — |
Stock-Based Compensation vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 stock-based compensation of $11.51M is the 3rd largest of the 11 companies compared; the peer median is $9.21M.
- Its year-over-year change of -28.1% is the 5th highest of 11, against a peer median of -32.8%.
- Stock-based compensation amounts to 5116.0% of revenue for TNYA, versus a peer median of 58.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.77M | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
| LTM Mar 2026 | $11.51M | -28.1% | +4.4% | 5116.0% | |
| LTM Mar 2026 | $11.16M | -32.8% | +2.7% | 99.6% | |
| LTM Mar 2026 | $10.44M | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $10.08M | -60.8% | -22.0% | 60.3% | |
| LTM Mar 2026 | $8.33M | +7.1% | +52.3% | 57.3% | |
| LTM Mar 2026 | $8.17M | -33.3% | -9.2% | 59.0% | |
| LTM Mar 2026 | $7.36M | +42.2% | — | 26.1% | |
| LTM Mar 2026 | $6.04M | -48.6% | -13.0% | — | |
| LTM Mar 2026 | $1.52M | -69.5% | — | — | |
| Peer median (excluding TNYA) | $9.21M | -32.8% | -3.3% | 58.1% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Depreciation & Amortization | 2.96M | 6.47M | 8.69M | 8.47M | 8.85M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.95M | 11.47M | 15.31M | 16.5M | 13.05M |
| Change in Working Capital | 4.74M | (849K) | (5.65M) | (7.93M) | (2.46M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.6M | 1.66M | (3.28M) | (581K) | (1.43M) |
| Other Working Capital | (3.86M) | (2.51M) | (2.37M) | (7.35M) | (1.03M) |
| Other Non-Cash Items | 1.26M | 2.16M | 3.66M | 3.59M | 2.9M |
| Operating Cash Flow | (60.81M) | (104.42M) | (102.07M) | (90.5M) | (68.26M) |
| Capital Expenditures | (25.12M) | (20.63M) | (1.24M) | (1.03M) | (618K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (213.44M) | (140.48M) | (56.64M) | (87.07M) | 0 |
| Sales of Investments | 0 | 244.75M | 106.62M | 89.21M | 56.7M |
| Other Investing Activities | 0 | 8K | (25K) | 17K | 0 |
| Investing Cash Flow | (238.56M) | 83.65M | 48.72M | 1.13M | 56.08M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 188.54M | 77.39M | 3.87M | 46.76M | 108.41M |
| Common Stock Repurchased | (13K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 461K | 380K | 181K | 987K | 0 |
| Financing Cash Flow | 208.97M | 77.77M | 4.05M | 47.75M | 108.41M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (90.41M) | 57M | (49.31M) | (41.62M) | 96.22M |
| Free Cash Flow | (85.93M) | (125.05M) | (103.31M) | (91.53M) | (68.88M) |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.